drugset / Trial / NCT04182100
Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 2 single arm study to investigate efficacy and safety of P1101 for adult Japanese patients with PV.
Timeline
- Start
- 2019-12-20
- Primary completion
- 2021-03-08
- Completion
- 2021-03-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ropeginterferon alfa-2b | Protein / enzyme biologic | 50 ug | Subcutaneous |
| Subject | Ropeginterferon alfa-2b | Protein / enzyme biologic | 100 ug | Subcutaneous |
| Subject | Ropeginterferon alfa-2b | Protein / enzyme biologic | 500 ug | Subcutaneous |
| Background | Aspirin | Small molecule | 75 mg | — |
| Background | Aspirin | Small molecule | 150 mg | — |